Table 1
(a) Baseline characteristics of the included studies

First AuthorCountryYearMulticenterNumber of PatientMean Age (years)Male (%)
nonagenarian groupcontrol groupnonagenarian groupcontrol groupnonagenarian groupcontrol group

Yamamoto et al.France2012No2611091.6±1.982.3±7.01950
Arsalan et al.United States2016Yes37732025292.0 (90.0-93.0)82.0 (76.0-86.0)48.2450.74
Ramkumar et al.Australia2016No238190.6±2.681.1±4.65244
Miura et al.Japan2017No258791.6±1.782.5±6.02037.9
Scholtz et al.Germany2017No8291291.8±1.484.8±2.619.558.8

(b) Baseline characteristics of patients in the included studies

First AuthorMean STS (%)Logistic EuroSCORELeft Ventricle EF (%)Mean Gradient (mm Hg)
nonagenarian groupcontrol groupnonagenarian groupcontrol groupnonagenarian groupcontrol groupnonagenarian groupcontrol group

Yamamoto et al.13.4±7.212.3±8.826.6±9.323.6±12.451.3±12.348.6±14.256.3±23.445.5±15.4
Arsalan et al.9.22 (6.73-13.25)6.34 (4.20-9.77)NRNR58(48-65)56(45-63)NRNR
Ramkumar et al.5.7±2.23.6±1.85.5±5.44.0±3.353.7±1759.1±1144.7±1449.6±16
Miura et al.10.0(7.5-12.0)6.0(3.0-7.0)20.0(16.0-25.5)14.0(11.0-22.0)63.2±6.961.8±9.059.6±19.054.2±19.9
Scholtz et al.8.5±4.86.3±4.527.7±14.823.1±14.454.6±9.552.5±11.447.1±17.345.1±16.8

(c) Medical history of patients in the included studies

First AuthorHypertension (%)Diabetes Mellitus (%)CAD (%)Stroke (%)NYHA III-IV (%)COPD (%)
nonagenarian groupcontrol groupnonagenarian groupcontrol groupnonagenarian groupcontrol groupnonagenarian groupcontrol groupnonagenarian groupcontrol groupnonagenarian groupcontrol group

Yamamoto et al.73762325NRNRNRNR65641930
Arsalan et al.86.5689.2619.3540.39NRNR9.3312.7780.9781.3715.430.1
Ramkumar et al.57811426222091774692723
Miura et al.7271.3426.42044.8415.17263.21217.2
Scholtz et al.82.979.61122.150.157NRNRNRNR15.914.5

CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease.